ghadmin
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has reached its target enrollment of 12,750 patients in ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Encounter), a registrational study to evaluate the performance of its LUNAR™-2 blood test to detect colorectal cancer (CRC) in average-risk adults.
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present new data demonstrating the benefits of using the Guardant360® liquid biopsy test to help guide targeted therapy options for patients with advanced breast cancer at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-11.
Precision Medicine is Transforming Cancer Care
How sophisticated technology and personalized treatment options are enabling more people with advanced cancer to manage and live with their diagnoses for the long-term.
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
The study, published in Nature Medicine, demonstrates that the Guardant360® test helps identify patients who may benefit from treatment and can identify alterations that predict resistance
Using Data to Conquer Cancer
Helmy Eltoukhy stops by The Morning Fix by 510k Café podcast to discuss the technologies Guardant Health is developing for patients with early and late-stage cancers. We also discuss the Clear Your View campaign, which raises awareness of the essential role complete biomarker testing plays in guiding initial treatment decisions for patients with advanced solid tumor cancers, including colorectal and lung cancers.
The Promise of Cancer Screening: Screen for Cancers Where Lives Can be Saved
Innovations in cancer therapeutics and precision diagnostics impact countless lives as more and more cancer patients are able to claim the title of cancer survivor. While we applaud this progress, for too many patients innovation has not won out over disease.
Disparities in clinical trials threaten African American lives
On World Cancer Research Day, we must correct course
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
Increased accessibility to Guardant Health’s liquid biopsy testing will enable clinicians to personalize treatments more accurately for patients with late-stage cancer
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
This study indicates Guardant Health’s blood test could provide meaningful clinical performance in an average risk screening population